DS
ALDX icon

David Shaw’s Aldeyra Therapeutics ALDX Stock Holding History

David Shaw’s Portfolio ALDX Stock Details ALDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.13M Buy
1,940,338
+536,348
+38% +$922K ﹤0.01% 2569
2026
Q1 		$2.37M Sell
1,403,990
-197,334
-12% -$865K ﹤0.01% 2782
2025
Q4 		$8.29M Buy
1,601,324
+221,481
+16% +$1.14M ﹤0.01% 1911
2025
Q3 		$7.2M Buy
1,379,843
+892,171
+183% +$4.65M ﹤0.01% 1921
2025
Q2 		$1.87M Buy
487,672
+336,030
+222% +$869K ﹤0.01% 2783
2025
Q1 		$872K Sell
151,642
-36,941
-20% -$218K ﹤0.01% 3170
2024
Q4 		$941K Sell
188,583
-146,198
-44% -$750K ﹤0.01% 3239
2024
Q3 		$1.8M Buy
334,781
+12,843
+4% +$61.1K ﹤0.01% 2777
2024
Q2 		$1.07M Sell
321,938
-225,702
-41% -$884K ﹤0.01% 3164
2024
Q1 		$1.79M Buy
547,640
+287,584
+111% +$946K ﹤0.01% 2721
2023
Q4 		$913K Buy
260,056
+214,089
+466% +$661K ﹤0.01% 3194
2023
Q3 		$307K Sell
45,967
-30,013
-40% -$223K ﹤0.01% 3603
2023
Q2 		$637K Sell
75,980
-48,942
-39% -$482K ﹤0.01% 3316
2023
Q1 		$1.24M Sell
124,922
-222,947
-64% -$1.58M ﹤0.01% 3012
2022
Q4 		$2.42M Sell
347,869
-100,241
-22% -$573K ﹤0.01% 2782
2022
Q3 		$2.39M Buy
448,110
+174,769
+64% +$1.05M ﹤0.01% 2839
2022
Q2 		$1.09M Buy
273,341
+34,183
+14% +$118K ﹤0.01% 3579
2022
Q1 		$1.06M Buy
239,158
+202,930
+560% +$808K ﹤0.01% 3865
2021
Q4 		$145K Buy
36,228
+21,947
+154% +$167K ﹤0.01% 4977
2021
Q3 		$125K Sell
14,281
-942
-6% -$8.64K ﹤0.01% 4678
2021
Q2 		$172K Sell
15,223
-2,929
-16% -$35.2K ﹤0.01% 4473
2021
Q1 		$216K Buy
+18,152
New +$209K ﹤0.01% 3822
2019
Q4 		– Sell
-18,111
Closed -$95K – 3938
2019
Q3 		$95K Buy
18,111
+7,007
+63% +$37.7K ﹤0.01% 3702
2019
Q2 		$67K Buy
+11,104
New +$83.6K ﹤0.01% 3573

Other funds holding ALDX

KCM
Knoll Capital Management Miami, Florida $179M AUM 63.61% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
KCM
Kingdon Capital Management New York $976M AUM 66.76% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
6CM
683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

David Shaw's ALDX Position: Q2 2026 in Review

David Shaw increased its Aldeyra Therapeutics (ALDX) stake by 38% in Q2 2026, buying an estimated $922K and bringing the position to 1,940,338 shares worth $4.13M. The position accounts for ﹤0.01% of the portfolio, ranked #2569.

David Shaw first reported a position in ALDX in Q2 2019 and has held it in 24 quarters since. The position peaked at $8.29M in Q4 2025. 108 funds tracked by Wall St. Rank hold ALDX as of Q2 2026.

  • David Shaw held 1,940,338 shares of Aldeyra Therapeutics worth $4.13M as of Q2 2026.
  • David Shaw bought 536,348 Aldeyra Therapeutics shares in Q2 2026, an estimated $922K.
  • Aldeyra Therapeutics made up ﹤0.01% of David Shaw's portfolio in Q2 2026, its #2569 holding.
  • David Shaw first reported a position in Aldeyra Therapeutics in Q2 2019 and has held it in 24 quarters since.
  • David Shaw's Aldeyra Therapeutics position peaked at $8.29M in Q4 2025.
  • 108 funds tracked by Wall St. Rank held Aldeyra Therapeutics as of Q2 2026.

Based on D.E. Shaw & Co's 13F filing for Q2 2026, filed 14 Aug 2026.